Clinical Characteristics of Lung Consolidation with Mycoplasma pneumoniae Pneumonia and Risk Factors for Mycoplasma pneumoniae Necrotizing Pneumonia in Children.
Clinical characteristics
Lung consolidation
Mycoplasma pneumoniae pneumonia
Necrotizing pneumonia
Risk factors
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
12
11
2023
accepted:
21
12
2023
medline:
24
1
2024
pubmed:
24
1
2024
entrez:
24
1
2024
Statut:
aheadofprint
Résumé
Mycoplasma pneumoniae necrotizing pneumonia (MPNP) is an uncommon but increasingly recognized severe complication of pneumonia, and the delayed diagnosis and treatment are prone to pulmonary sequelae. The aim of this study is to explore independent risk factors for MPNP in children with lung consolidation. A retrospective observational study was conducted on 118 children with MPNP (MPNP group) and 184 children with lung consolidation of Mycoplasma pneumoniae pneumonia (MPP) (control group) admitted to Children's Hospital Affiliated to Zhengzhou University from June 2018 to August 2023. Clinical manifestations and laboratory data were analyzed and the independent risk factors for MPNP in children were analyzed by multivariate logistic regression. The age of onset, hospitalization days, fever days, proportion of dyspnea, chest pain, complications, and need for fiberoptic bronchoscopic alveolar lavage (FBAL) were higher than those in the control group, and the difference was statistically significant (P < 0.05). The levels of white blood cells (WBC), platelets, neutrophil percentage (N%), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), fibrinogen (Fbg), D-dimer (D-D), erythrocyte sedimentation rate (ESR), alanine transaminase (ALT), γ-glutamyl transpeptidase (γ-GGT), globulin, lactate dehydrogenase (LDH), α-hydroxybutyrate dehydrogenase (α-HBDH), urea, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), complement component 3, antistreptolysin O (ASO), serum ferritin, and interleukin-6 (IL-6) in the MPNP group were higher than those in the control group. Red blood cell (RBC), lymphocyte percentage (L%), activated partial thromboplastin time (APTT), alkaline phosphatase (ALP), total protein, albumin, albumin-to-globulin ratio (AGR), creatine kinase (CK), uric acid, natrium, chlorine, calcium, and complement C4 in the MPNP group were lower than those in the control group, and the difference was statistically significant (P < 0.05). The results of multivariate logistic regression analysis showed that age ≥ 83.50 months, fever days ≥ 10.50, ALT ≥ 15.25 U/l, IgM ≥ 1.46 g/l, complement C3 ≥ 1.47 g/l, Fbg ≥ 3.93 g/l, dyspnea and needing FBAL were independent risk factors for MPNP in children. Age, fever days, ALT, IgM, complement C3, Fbg, dyspnea, and needing FBAL were independent risk factors for MPNP in children. For children suspected of MPNP, pediatricians should pay close attention to the above indicators, strive for early diagnosis and treatment, and improve prognosis.
Identifiants
pubmed: 38265626
doi: 10.1007/s40121-023-00914-x
pii: 10.1007/s40121-023-00914-x
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Waites KB, et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017;30(3):747–809.
doi: 10.1128/CMR.00114-16
pubmed: 28539503
pmcid: 5475226
Li ZJ, et al. Etiological and epidemiological features of acute respiratory infections in China. Nat Commun. 2021;12(1):5026.
doi: 10.1038/s41467-021-25120-6
pubmed: 34408158
pmcid: 8373954
Kutty PK, et al. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia. Clin Infect Dis. 2019;68(1):5–12.
pubmed: 29788037
Moynihan KM, et al. Severe Mycoplasma pneumoniae infection in children admitted to pediatric intensive care. Pediatr Infect Dis J. 2018;37(12):e336–8.
doi: 10.1097/INF.0000000000002029
pubmed: 29912842
Masters IB, Isles AF, Grimwood K. Necrotizing pneumonia: an emerging problem in children? Pneumonia (Nathan Qld). 2017;9:11.
doi: 10.1186/s41479-017-0035-0
pubmed: 28770121
Wang X, et al. Necrotizing pneumonia caused by refractory Mycoplasma pneumoniae pneumonia in children. World J Pediatr. 2018;14(4):344–9.
doi: 10.1007/s12519-018-0162-6
pubmed: 29948966
China NHCOTPSRU. Guidelines for diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023 Edition). China Licens Pharm. 2023;20(3):16–24.
Sawicki GS, et al. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur Respir J. 2008;31(6):1285–91.
doi: 10.1183/09031936.00099807
pubmed: 18216055
Jing Q, et al. Analysis of clinical features and risk factors of necrotizing pneumonia in children. J Peking Univ (Health Sci). 2022;54(03):541–7.
Hsieh Y-C, et al. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan. Clin Infect Dis. 2004;38(6):830–5.
doi: 10.1086/381974
pubmed: 14999627
Zheng B, Zhao J, Cao L. The clinical characteristics and risk factors for necrotizing pneumonia caused by Mycoplasma pneumoniae in children. BMC Infect Dis. 2020;20(1):391.
doi: 10.1186/s12879-020-05110-7
pubmed: 32487034
pmcid: 7268704
Yang B, et al. Differences of clinical features and prognosis between Mycoplasma pneumoniae necrotizing pneumonia and non-Mycoplasma pneumoniae necrotizing pneumonia in children. BMC Infect Dis. 2021;21(1):797.
doi: 10.1186/s12879-021-06469-x
pubmed: 34376156
pmcid: 8356421
Sauteur PMM, et al. Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children. Clin Infect Dis. 2020;71(7):1645–54.
doi: 10.1093/cid/ciz1059
Chen J, et al. Mycoplasma pneumoniae infection prediction model for hospitalized community-acquired pneumonia children. Pediatr Pulmonol. 2021;56(12):4020–8.
doi: 10.1002/ppul.25665
pubmed: 34547836
Feibo G, et al. Value of changes of serum complement, immunoglobulin and inflammatory cytokines in children with Mycoplasma pneumonia. Chin J Immunol. 2017;33(6):910–3.
Lan-fang L, Xiao-bing L, Lan-qing Z. Analysis of changes of serum immunoglobulin, erythrocyte immunity and peripheral blood T lymphocyte subsets after Mycoplasma pneumoniae infection in children. Mater Child Health Care China. 2015;30(3):385–7.
Xin T. Changes and clinical significance of sTREM-1, fibrinogen and D-dimer levels in severe pneumonia patients. J Clin Pulm Med. 2018;23(9):1699–702.
Li H, Jun Z, Tie-shuan Z. Changes of D-dimer, fibrinogen and IL-6 levels in patients with severe pneumonia and their clinical significance. Chin J Respir Crit Care Med. 2017;16(1):71–3.
Na W. Changes and clinical significance of related index levels of blood coagulation function and immune function in children with Mycoplasma pneumoniae pneumonia. China Med Herald. 2016;13(32):94–7.
Zhi-long W, Zhi-ying H, Wei W. Analysis on the risk factors of Mycoplasma pneumoniae necrotizing pneumonia in children. Chin J New Clin Med. 2023;16(5):500–5.
Huang X, et al. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2021;21(1):14.
doi: 10.1186/s12879-020-05700-5
pubmed: 33407216
pmcid: 7787414
Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016;7:800.
doi: 10.3389/fmicb.2016.00800
pubmed: 27313568
pmcid: 4888638
Yu C, et al. Clinical features and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Chin J Contemp Pediatr. 2018;20(8):629–34.
Yan H. The advantages of bronchoalveolar lavage in the diagnosis and treatment of Mycoplasma pneumoniae pneumonia. Med Philos. 2018;39(01):16–8.
Kim YJ, Park KS, Cho SY. Mean platelet volume in pediatric patients infected with Mycoplasma pneumoniae. Clin Lab. 2021. https://doi.org/10.7754/Clin.Lab.2020.200944 .
doi: 10.7754/Clin.Lab.2020.200944
pubmed: 34758229
Zheng HH, et al. Clinical value of blood related indexes in the diagnosis of bacterial infectious pneumonia in children. Transl Pediatr. 2022;11(1):114–9.
doi: 10.21037/tp-21-568
pubmed: 35242657
pmcid: 8825944
Li F, et al. Mycoplasma pneumoniae and adenovirus coinfection cause pediatric severe community-acquired pneumonia. Microbiol Spectr. 2022;10(2): e0002622.
doi: 10.1128/spectrum.00026-22
pubmed: 35311565
Choo S, Lee YY, Lee E. Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia. BMC Pulm Med. 2022;22(1):212.
doi: 10.1186/s12890-022-02005-y
pubmed: 35637540
pmcid: 9150047